High-Frequency Nanosecond Bleomycin Electrochemotherapy and its Effects on Changes in the Immune System and Survival

Simple Summary Standard microsecond electrochemotherapy (μsECT) is used in clinical trials for the elimination of tumours, while the first studies on nanosecond electrochemotherapy (nsECT) only started to appear recently. Nanosecond pulses enable more homogeneous treatment and better control of pulse burst energy, and thus the whole field of electroporation is moving towards the shorter pulse range. In order to ensure a full anticancer response and potentially prevent any metastases, the immunomodulatory effects should also be induced. Therefore, in this work, we used nsECT protocols based on kHz and MHz pulse bursts and characterized the response of the immune system to the novel modality of nano-electrochemotherapy. The results of this study are useful for the development of effective anticancer treatment strategies based on high frequency nanosecond electric fields. Abstract In this work, a time-dependent and time-independent study on bleomycin-based high-frequency nsECT (3.5 kV/cm × 200 pulses) for the elimination of LLC1 tumours in C57BL/6J mice is performed. We show the efficiency of nsECT (200 ns and 700 ns delivered at 1 kHz and 1 MHz) for the elimination of tumours in mice and increase of their survival. The dynamics of the immunomodulatory effects were observed after electrochemotherapy by investigating immune cell populations and antitumour antibodies at different timepoints after the treatment. ECT treatment resulted in an increased percentage of CD4+ T, splenic memory B and tumour-associated dendritic cell subsets. Moreover, increased levels of antitumour IgG antibodies after ECT treatment were detected. Based on the time-dependent study results, nsECT treatment upregulated PD 1 expression on splenic CD4+ Tr1 cells, increased the expansion of splenic CD8+ T, CD4+CD8+ T, plasma cells and the proportion of tumour-associated pro inflammatory macrophages. The Lin− population of immune cells that was increased in the spleens and tumour after nsECT was identified. It was shown that nsECT prolonged survival of the treated mice and induced significant changes in the immune system, which shows a promising alliance of nanosecond electrochemotherapy and immunotherapy.

[1]  J. Kulbacka,et al.  Nanosecond electrochemotherapy using bleomycin or doxorubicin: Influence of pulse amplitude, duration and burst frequency. , 2022, Bioelectrochemistry.

[2]  D. Miklavčič,et al.  Nanosecond Electric Pulses are Equally Effective in Electrochemotherapy with Cisplatin as Microsecond Pulses , 2022, Radiology and oncology.

[3]  W. Seeger,et al.  Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry , 2022, Frontiers in Immunology.

[4]  D. Miklavčič,et al.  Effects of Time Delay Between Unipolar Pulses in High Frequency Nano-Electrochemotherapy , 2021, IEEE Transactions on Biomedical Engineering.

[5]  A. Petrovsky,et al.  The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer , 2021, Journal of Modern Oncology.

[6]  R. Davalos,et al.  Generation of Tumor-activated T cells using electroporation. , 2021, Bioelectrochemistry.

[7]  D. Miklavčič,et al.  Electroporation with nanosecond pulses and bleomycin or cisplatin results in efficient cell kill and low metal release from electrodes. , 2021, Bioelectrochemistry.

[8]  Sheng-ping Li,et al.  The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer , 2021, Oncoimmunology.

[9]  A. Eresen,et al.  Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer , 2021, Oncoimmunology.

[10]  L. Schultz,et al.  Increased Tumor Immune Microenvironment CD3+ and CD20+ Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell Carcinoma , 2021, Frontiers in Cell and Developmental Biology.

[11]  T. Jiang,et al.  Antitumor Effect and Immune Response of Nanosecond Pulsed Electric Fields in Pancreatic Cancer , 2021, Frontiers in Oncology.

[12]  H. Tomita,et al.  PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. , 2020, Gastroenterology.

[13]  V. Novickij,et al.  Electrochemotherapy Using Doxorubicin and Nanosecond Electric Field Pulses: A Pilot in Vivo Study , 2020, Molecules.

[14]  Yu Zhang,et al.  T‐cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer , 2020, Clinical and translational medicine.

[15]  B. Dréno,et al.  Transcriptomic features of tumour-infiltrating CD4lowCD8high double positive αβ T cells in melanoma , 2020, Scientific Reports.

[16]  D. Miklavčič,et al.  High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. , 2020, Radiology.

[17]  F. Rosenbauer,et al.  CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow. , 2020, The Journal of allergy and clinical immunology.

[18]  É. Vivier,et al.  SnapShot: Natural Killer Cells , 2020, Cell.

[19]  M. Čemažar,et al.  Recent Advances in Electrochemotherapy. , 2019, Bioelectricity.

[20]  S. Šatkauskas,et al.  Antitumor Response and Immunomodulatory Effects of Sub-Microsecond Irreversible Electroporation and Its Combination with Calcium Electroporation , 2019, Cancers.

[21]  L. Terracciano,et al.  Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma , 2019, Cellular and molecular gastroenterology and hepatology.

[22]  Aaron M. Miller,et al.  Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model , 2019, Cancer Immunology Research.

[23]  D. Kitamura,et al.  The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets , 2019, eLife.

[24]  M. Ahluwalia,et al.  Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells , 2019, bioRxiv.

[25]  Rebecca M. Brock,et al.  High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity , 2019, EBioMedicine.

[26]  W. Roth,et al.  PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity , 2019, Front. Oncol..

[27]  X. Mo,et al.  CD31 Acts as a Checkpoint Molecule and Is Modulated by FcγR-Mediated Signaling in Monocytes , 2019, The Journal of Immunology.

[28]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[29]  F. Balkwill,et al.  Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells , 2019, Front. Immunol..

[30]  E. Esin,et al.  Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience , 2019, Journal of oncology.

[31]  Morgan A. O'Brien,et al.  Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer. , 2019, Cancer letters.

[32]  Samira M. Azarin,et al.  Engineering T cell response to cancer antigens by choice of focal therapeutic conditions , 2019, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[33]  V. Schirrmacher.  From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) , 2018, International journal of oncology.

[34]  P. Linsley,et al.  Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers , 2018, Front. Immunol..

[35]  Jing Zhu,et al.  A Review on Electroporation-Based Intracellular Delivery , 2018, Molecules.

[36]  Eric Vivier,et al.  High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice , 2018, Immunity.

[37]  Y. Mi,et al.  Scaling Relationship of In Vivo Muscle Contraction Strength of Rabbits Exposed to High-Frequency Nanosecond Pulse Bursts , 2018, Technology in cancer research & treatment.

[38]  Cara C. Schafer,et al.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5 , 2018, The Journal of Immunology.

[39]  Jia-yan Guo,et al.  Identification of CD24 as a marker for tumorigenesis of melanoma , 2018, OncoTargets and therapy.

[40]  J. Koch,et al.  CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells , 2018, Cancer Immunology Research.

[41]  R. Heller,et al.  Nano‐pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases , 2018, International journal of cancer.

[42]  M. Čemažar,et al.  Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma. , 2018, Bioelectrochemistry.

[43]  R. Nuccitelli,et al.  Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response , 2018, PloS one.

[44]  S. Szala,et al.  M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma , 2018, PloS one.

[45]  Scott N. Mueller,et al.  Migratory CD11b+ conventional dendritic cells induce T follicular helper cell–dependent antibody responses , 2017, Science Immunology.

[46]  K. Mäbert,et al.  TCR+CD3+CD4-CD8- effector T cells in psoriasis. , 2017, Clinical immunology.

[47]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[48]  James A McCaul,et al.  European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. , 2016, European journal of cancer.

[49]  Jin Xu,et al.  Multi-parametric study of temperature and thermal damage of tumor exposed to high-frequency nanosecond-pulsed electric fields based on finite element simulation , 2016, Medical & Biological Engineering & Computing.

[50]  P. Leveque,et al.  Multiphoton imaging reveals that nanosecond pulsed electric fields collapse tumor and normal vascular perfusion in human glioblastoma xenografts , 2016, Scientific Reports.

[51]  Kaori Ito,et al.  Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma , 2016, Oncology.

[52]  B. Rocha,et al.  Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8+CD11c+ PD-1lo Effector T Cells , 2016, PloS one.

[53]  L. Mir,et al.  The promising alliance of anti-cancer electrochemotherapy with immunotherapy , 2016, Cancer and Metastasis Reviews.

[54]  Audrius Grainys,et al.  High-frequency submicrosecond electroporator , 2016 .

[55]  M. Rols.  Gene Delivery by Electroporation In Vitro: Mechanisms , 2016 .

[56]  Richard Nuccitelli,et al.  Nanoelectroablation of Murine Tumors Triggers a CD8-Dependent Inhibition of Secondary Tumor Growth , 2015, PloS one.

[57]  Hao Wu,et al.  Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. , 2015, Immunity.

[58]  U. Pliquett,et al.  Measurement and simulation of Joule heating during treatment of B-16 melanoma tumors in mice with nanosecond pulsed electric fields. , 2014, Bioelectrochemistry.

[59]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[60]  Richard Heller,et al.  A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields. , 2014, European journal of cancer.

[61]  Damijan Miklavčič,et al.  Electroporation-based technologies for medicine: principles, applications, and challenges. , 2014, Annual review of biomedical engineering.

[62]  M. Hallek,et al.  Characterization of tumor-associated B-cell subsets in patients with colorectal cancer , 2014, Oncotarget.

[63]  Haiyang Xie,et al.  Nanosecond pulsed electric field (nsPEF) treatment for hepatocellular carcinoma: a novel locoregional ablation decreasing lung metastasis. , 2014, Cancer letters.

[64]  L. Mir,et al.  Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells , 2014, Oncoimmunology.

[65]  D. Miklavčič,et al.  Evidence of Conducting Hydrophobic Nanopores Across Membranes in Response to an Electric Field , 2014 .

[66]  M. Clément,et al.  CD31 is a key coinhibitory receptor in the development of immunogenic dendritic cells , 2014, Proceedings of the National Academy of Sciences.

[67]  Lei Lu,et al.  Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs , 2014, Journal of Translational Medicine.

[68]  Shuming Ye,et al.  Comparative Study of Nanosecond Electric Fields In Vitro and In Vivo on Hepatocellular Carcinoma Indicate Macrophage Infiltration Contribute to Tumor Ablation In Vivo , 2014, PloS one.

[69]  O. Tsitsilonis,et al.  The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients , 2014, Experimental Hematology & Oncology.

[70]  An-jun Liu,et al.  Effect of spleen lymphocytes on the splenomegaly in hepatocellular carcinoma-bearing mice. , 2014, Biomedical and environmental sciences : BES.

[71]  P. Basse,et al.  NK cells in the tumor microenvironment. , 2014, Critical reviews in oncogenesis.

[72]  Vrajesh V. Parekh,et al.  In Vitro Induction of Regulatory CD4+CD8α+ T Cells by TGF-β, IL-7 and IFN-γ , 2013, PloS one.

[73]  M. Čemažar,et al.  Differential Mechanisms Associated with Vascular Disrupting Action of Electrochemotherapy: Intravital Microscopy on the Level of Single Normal and Tumor Blood Vessels , 2013, PloS one.

[74]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[75]  S. Carotta,et al.  Regulation of murine natural killer cell commitment , 2013, Front. Immun..

[76]  A. T. Esser,et al.  A brief overview of electroporation pulse strength-duration space: a region where additional intracellular effects are expected. , 2012, Bioelectrochemistry.

[77]  Richard Nuccitelli,et al.  Non‐thermal Nanoelectroablation of UV‐induced Murine Melanomas Stimulates an Immune Response , 2012, Pigment cell & melanoma research.

[78]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[79]  J. Gehl,et al.  Management of cutaneous metastases using electrochemotherapy , 2011, Acta oncologica.

[80]  G. Mundy,et al.  Gr-1+CD11b+ Myeloid-Derived Suppressor Cells: Formidable Partners in Tumor Metastasis , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  R. Nussenblatt,et al.  Scleritis and multiple systemic autoimmune manifestations in chronic natural killer cell lymphocytosis associated with elevated TCRα/β+CD3+CD4−CD8− double-negative T cells , 2010, British Journal of Ophthalmology.

[82]  Lieping Chen,et al.  PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells , 2010, Nature Immunology.

[83]  L. Boon,et al.  GITR Triggering Induces Expansion of Both Effector and Regulatory CD4+ T Cells In Vivo1 , 2009, The Journal of Immunology.

[84]  I. Fidler,et al.  Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. , 2009, The American journal of pathology.

[85]  M. Čemažar,et al.  Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. , 2009, Tumori.

[86]  Laurence Zitvogel,et al.  Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses , 2008, Cancer Immunology, Immunotherapy.

[87]  D Miklavcic,et al.  Electrochemotherapy in treatment of tumours. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[88]  K. Hunter,et al.  Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. , 2007, Experimental and molecular pathology.

[89]  Damijan Miklavčič,et al.  Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study , 2006 .

[90]  A. Lackner,et al.  Intestinal double‐positive CD4+CD8+ T cells are highly activated memory cells with an increased capacity to produce cytokines , 2006, European journal of immunology.

[91]  Shulin Li,et al.  Regression of High-Grade Malignancy in Mice by Bleomycin and Interleukin-12 Electrochemogenetherapy , 2006, Clinical Cancer Research.

[92]  U. Pliquett,et al.  Joule heating during solid tissue electroporation , 2003, Medical and Biological Engineering and Computing.

[93]  G. Bishop,et al.  A Costimulatory Function for T Cell CD40 , 2006 .

[94]  M. Čemažar,et al.  Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice , 2005, BMC Cancer.

[95]  J. Stubbe,et al.  Bleomycins: towards better therapeutics , 2005, Nature Reviews Cancer.

[96]  Damijan Miklavcic,et al.  The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo for a potential use in clinical electrochemotherapy. , 2005, Bioelectrochemistry.

[97]  C. Riccardi,et al.  Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations , 2004, European journal of immunology.

[98]  Julie Gehl,et al.  Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. , 2003, Cancer treatment reviews.

[99]  L. Mir,et al.  In vivo evolution of tumour cells after the generation of double-strand DNA breaks , 2003, British Journal of Cancer.

[100]  P. Pandolfi,et al.  Role of GITR in activation response of T lymphocytes. , 2002, Blood.

[101]  M J Jaroszeski,et al.  Toxicity of anticancer agents mediated by electroporation in vitro , 2000, Anti-cancer drugs.

[102]  K. Okumura,et al.  Costimulatory molecules CD80 and CD86 in the rat; tissue distribution and expression by antigen‐presenting cells , 1998, Journal of leukocyte biology.

[103]  Y. Takasaki.  [Costimulatory molecules, CD 80 and CD 86]. , 1998, Ryumachi. [Rheumatism].

[104]  L. Mir,et al.  Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompotent and immunodeficient mice , 1997 .

[105]  J. Ceuppens,et al.  CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model , 1996, Immunological reviews.

[106]  C. Lindqvist,et al.  Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs. , 1992, European journal of cancer. Part B, Oral oncology.

[107]  L. Mir,et al.  [Electrochemotherapy, a new antitumor treatment: first clinical trial]. , 1991, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[108]  W. Mackay.  Role of Splenomegaly in Tumour-bearing Mice , 1965, Nature.